Zepzelca’s pivotal surprise
Jazz's somewhat low-key SCLC drug scores its biggest win yet.
ESMO 2024 – MediLink impresses in small-cell lung cancer
The group’s B7-H3 ADC looks competitive versus rival projects from Merck/Daiichi and GSK/Hansoh.
ESMO 2024 – Bristol heads for phase 3 in small-cell
Backed by a slender survival signal the industry’s only anti-fucosyl-GM1 MAb is to go pivotal.
World Lung 2024 – backing for ifinatamab’s pivotal move
The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.
Fresh questions over DLL3
Five years after AbbVie pulled the plug on rova-T, DLL3 comes under the spotlight again.
ASCO 2024 – some Adriatic fears allayed
Fears that Adriatic’s statistical survival wins would be clinically marginal haven’t materialised.
